Drugs in MeSH Category Dopamine Uptake Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurolife Pharma Llc	DEXMETHYLPHENIDATE HYDROCHLORIDE	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	202580-008	Aug 25, 2015		DISCN	No	No
Sun Pharm Industries	DEXMETHYLPHENIDATE HYDROCHLORIDE	dexmethylphenidate hydrochloride	TABLET;ORAL	201231-001	Sep 24, 2015	AB	RX	No	No
Teva Pharms Usa	DEXMETHYLPHENIDATE HYDROCHLORIDE	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	078908-004	May 19, 2014	AB	RX	No	No
Rhodes Pharms	LISDEXAMFETAMINE DIMESYLATE	lisdexamfetamine dimesylate	CAPSULE;ORAL	215330-007	Aug 25, 2023	AB	RX	No	No

Last updated: June 23, 2026

ecutive summary Dopamine uptake inhibitors are a narrow but commercially meaningful segment spanning reuptake inhibitors that target monoamine transporters, most notably DAT (dopamine transporter) and, in some products, combined monoamine profiles. Patent and market dynamics are shaped by (1) long-running formulation and manufacturing estates, (2) method-of-use and dosing regimens, and (3) periods of exclusivity that often extend effective brand control beyond first patent expirations. Competitive pressure concentrates around Paragraph IV filings for oral small molecules and around biosimilar-style “switch” risk where alternative delivery systems or prodrugs change the commercial entry route. The most investable risk points are near patent cliffs for lead compounds plus any blocking continuations covering extended-release, abuse-deterrent, and specific patient subpopulations.

What dopamine uptake inhibitors are in MeSH Class terms, and how is the market segmented

Dopamine uptake inhibitors typically map to small-molecule monoamine transporter inhibitors used for attention, narcolepsy, and other neurologic indications, with several products marketed as combination or re-optimized formulations rather than new molecular entities.

Which active ingredients commonly show up

Common overlaps for “dopamine uptake inhibition” in commercial practice include:

• DAT-selective or DAT-dominant inhibitors
• Dual DAT/NET inhibitors (dopamine plus norepinephrine effects)
• Indication-specific re-formulations (immediate-release versus extended-release; abuse-deterrent; prodrugs)

Market segmentation by formulation rather than by molecule

In this class, differentiation is frequently driven by:

• Release profile (IR, ER, XR, suspension)
• Dose titration convenience
• Safety and diversion/abuse mitigation claims
• PK and administration constraints (morning dosing, school-day coverage)

How long do patents and exclusivities last for dopamine uptake inhibitor brands

Featured-snippet answer: Brand control typically runs from patent filing priority through 20-year term plus at least one layer of statutory exclusivity or patent-term adjustments, often extended by formulation and method-of-use patents.

Typical exclusivity structure

• Regulatory exclusivity (New Chemical Entity/New Molecular Entity) for initial approvals
• Pediatric exclusivity (where granted)
• Orphan exclusivity (only for specific rare indications)
• Patent-term adjustments and extensions for qualifying delays

Why the effective cliff is rarely the first composition patent

In dopamine reuptake inhibitor markets, later patents commonly cover:

• Extended-release matrices
• Coacervate systems, osmotic pumps, or multiparticulate delivery
• Abuse-deterrent modifications (physical barriers, gelling mechanisms)
• Process claims (granulation, drying, compression, coating, packaging)

What patents protect dopamine uptake inhibitors: composition, method, and formulation

Featured-snippet answer: Patent estates usually combine (1) composition-of-matter for the drug substance, (2) formulation-of-matter for the dosage form, (3) process claims, and (4) method-of-use claims tied to specific indications, dosing windows, or patient populations.

Composition-of-matter patents

• Core active ingredient coverage
• Salt form or polymorph coverage (where applicable)
• Prodrug linkers or stereochemical variants (if the marketed product is a defined stereoisomer or specific salt)

Formulation patents

Common in this class:

• Extended-release technology
• Particle size distribution and blending ratios
• Specific excipient systems
• Stability and shelf-life extensions via protective coatings or moisture control
• Film coating, hard capsule filling, or tablet compression methods

Method-of-use patents

Method-of-use estates can be more durable because they are harder to design around for an intended indication:

• Dose-ranging and titration steps
• Treatment of defined symptom clusters
• Pediatric regimen patterns
• Switching protocols from IR to ER, or from one therapeutic class to another

When does dopamine uptake inhibitor exclusivity lose protection and what drives launch timing

Featured-snippet answer: Exclusivity loss depends on the last-listed blocking patent in the FDA Orange Book and any statutory exclusivity expiration, not the earliest patent in the estate.

Timing drivers

• Last composition or formulation “blocking” patent expiration
• If any listed patent covers the exact dosage strength and formulation route (IR vs ER)
• Any granted Pediatric Exclusivity that extends the non-patent exclusivity window
• Any settlement that triggers “carve-out” launch dates

Generic and authorized competitor entry planning

Commercial entrants model three dates:

1. Non-patent exclusivity end
2. Blocking Orange Book patent expiration
3. Likely “design-around” readiness for formulation and process claims

What is the Orange Book status of dopamine uptake inhibitors

Featured-snippet answer: Orange Book status is decisive for generic timing because it identifies the listed patents that must be challenged under the Hatch-Waxman framework.

How to interpret Orange Book listings for this class

Key field patterns that affect risk:

• Patent numbers tied to specific NDCs (strength-by-strength blocking)
• Patent type codes (drug substance vs drug product vs method)
• Whether the listed patents are formulation-specific (IR versus ER)
• Whether multiple patents block a single NDC

Commercial implications of Orange Book fragmentation

Where one brand has multiple NDCs, generic entry can be staggered by:

• Strength-specific blocking patents
• Separate IR and ER product listings
• Additional patents for sprinkle formulations or suspension kits

How strong is the patent estate for dopamine uptake inhibitor brands

Featured-snippet answer: Estates are “strongest” when they include both composition and formulation blocks for the same NDC set, plus process claims that limit generic manufacturing workarounds.

Strength indicators investors and litigators use

• Number of listed patents per NDC
• Whether later patents cover the marketed ER technology
• Whether method-of-use claims map to core indications
• Whether the estate includes multiple continuations with staggered expiry dates
• Prosecution strategy: whether claims are broad but commercially unused, which increases litigation leverage

Weakness indicators

• Single-point dependency on a formulation that can be redesigned
• Lack of listed method-of-use coverage in core indications
• Narrow claims limited to a specific excipient ratio or particle size

Which companies are challenging dopamine uptake inhibitor patents with Paragraph IV

Featured-snippet answer: Paragraph IV challenges concentrate where Orange Book has multiple blocking patents for commercial NDCs and where the brand has high market share in ER strengths.

What drives successful Paragraph IV challenges in this space

• Generic candidates that can maintain bioequivalence while using a different release mechanism
• Strong prior-art positioning on specific formulation or manufacturing steps
• Settlement leverage when brand needs continued market coverage across multiple NDC strengths

What patent litigation affects dopamine uptake inhibitors

Featured-snippet answer: Litigation outcomes most often determine whether generics can enter at the first possible date or only after additional design-around time.

Litigation patterns that recur

• Motions around claim construction tied to formulation features
• Disputes about whether the generic filing infringes by equivalency or literal claim language
• Settlement-triggered “at-risk” launch delays
• Staggered releases by strength after settlement carve-outs

Commercial outcomes

• Early entry with narrow NDC coverage (one strength, IR only)
• Delayed ER entry due to formulation blocks
• Market share shifts that track launch timing rather than patent expiration date alone

How does ER versus IR protection change generic entry risk

Featured-snippet answer: ER products typically carry more dense formulation estates, making them a higher-risk target for early generic entry than IR strengths.

Why ER is harder to design around

• Release control mechanisms are claim-intensive
• Abuse-deterrent and PK matching create additional claim layers
• Many patents are tied to internal structuring, coating systems, and manufacturing steps that are difficult to replicate exactly

What formulations are protected for dopamine uptake inhibitors

Featured-snippet answer: Formulation protection tends to cover not only the ER/IR distinction but the specific excipient matrix, coating and granulation parameters, and sometimes patient-handling products (capsule sprinkle, suspension).

Protected formulation categories to expect

• Matrix tablets and osmotic-release systems
• Multiparticulate systems (beads/minipills)
• Abuse-deterrent variants
• Fixed-dose combination tablets where the dopamine uptake inhibitor is paired with another active

How do dopamine uptake inhibitor products compare and where patent estates diverge

Featured-snippet answer: Patent estates diverge less on the active ingredient and more on delivery system and method-of-use scope.

Comparison axes

• Same active ingredient across IR and ER: same composition estate, different formulation estate
• Same indication across age groups: method-of-use may differ for pediatric regimens
• Same brand marketed under different NDC sets: distinct blocking patterns

What generic entry risks exist for dopamine uptake inhibitors

Featured-snippet answer: The highest risks occur when a generic must match a tightly claimed ER formulation or when method-of-use claims remain listed and asserted.

Risk map by design-around target

• Release mechanism redesign: medium to high
• Excipient and coating parameter redesign: high
• Switching route (IR to ER or ER to IR) by generic: blocked by NDC-specific listing
• Method-of-use carve-outs: possible if a generic label can be limited without losing market access

How do manufacturing and process patents block competitors

Featured-snippet answer: Process claims can prevent “easy copy” manufacturing even where the formulation concept is similar.

Where process patents matter

• Granulation and drying parameters used to control dissolution rate
• Tabletting parameters that define release kinetics
• Coating and film application processes
• Packaging and stability processes for ER products

Licensing deals and settlement agreements: what to expect and how they change timelines

Featured-snippet answer: Settlements often result in delayed launch dates tied to specific NDC sets, with either strength carve-outs or ER/IR separation.

Deal structures commonly seen

• Licensing for an authorized generic after patent expiry
• Settlement with a “design-around allowed” scope
• Royalty-bearing licenses that permit earlier entry than a generic settlement
• Division of markets: IR vs ER, or monotherapy vs combination

Market impact

• Authorized generics can undercut pricing immediately upon settlement entry
• Settlement dates can become the de facto launch schedule even where statutory windows remain

Regulatory pathway pressure: what FDA review does to patent strategy

Featured-snippet answer: For small-molecule dopamine uptake inhibitors, FDA bioequivalence requirements constrain formulation design around, increasing the role of specific formulation and process patents.

Generic approval constraints

• Bioequivalence for IR and ER needs matched dissolution profiles and PK exposure
• Strength-by-strength and route-by-route constraints translate directly into Orange Book NDC blocking strategy

Biosimilar risk: does it apply to dopamine uptake inhibitors

Featured-snippet answer: Biosimilar frameworks generally do not apply because dopamine uptake inhibitors in this MeSH class are typically small molecules, not biologics.

Revenue exposure: where the business is most sensitive to patent cliffs

Featured-snippet answer: Revenue exposure concentrates in the highest-volume commercial strengths and in ER SKUs, where market adoption and switching patterns make formulation lock-in more valuable.

Exposure drivers

• ER coverage for daytime adherence
• Formulary positioning and rebate structures
• Pediatric and school-year prescribing cycles

Key Takeaways

• Patent estates in dopamine uptake inhibitor markets are typically multi-layered: composition plus formulation plus method-of-use and process claims.
• Effective exclusivity and generic entry timing depend on the last blocking Orange Book-listed patents by NDC, not the earliest priority or first patent expiry.
• ER products carry higher design-around difficulty and usually have denser formulation estates.
• Litigation and settlements frequently produce NDC-specific launch outcomes, shifting commercial timing away from simple statutory calculations.
• The most investable risk points are the ER formulation and NDC-specific blocking patterns plus any method-of-use claims tied to core indication labels.

FAQs

1. How do NDC-specific Orange Book listings affect generic timing for dopamine uptake inhibitors?
2. What claim types (formulation, method-of-use, process) most often block ER generics in this class?
3. How do settlement carve-outs typically split IR vs ER launches for dopamine uptake inhibitor brands?
4. What formulation features are most likely to be claim-relevant for release control in dopamine uptake inhibitor ER products?
5. When multiple patents list against one NDC, how do entrants prioritize Paragraph IV challenges in practice?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book).
2. FDA. Hatch-Waxman Drug Patent Litigation and Paragraph IV. (FDA resources).
3. United States Patent and Trademark Office. Patent term and exclusivity framework overview (statutory background).